GO
Loading...

Pharmaceuticals

More

  • Pfizer Wheelin' and Dealin' For Encysive's Thelin Wednesday, 20 Feb 2008 | 10:54 AM ET

    The world's biggest drug company is spending chump change to take out a little biotech at a 118 percent premium. Pfizer, which has a cash hoard of more than $20 billion, is plunking down a paltry (for Pfizer, that is) $195 million in cash money to buy Encysive Pharmaceuticals.

  • Black Tuesday for Onyx Tuesday, 19 Feb 2008 | 12:27 PM ET

    Almost exactly one year since Onyx Pharmaceuticals announced positive results of its drug Nexavar for liver cancer and the stock doubled in one day, the biopharmaceutical company is providing an example of the ups and downs of drug development and biotech investing.

  • European Stocks Rally as Banks Surge Monday, 18 Feb 2008 | 12:13 PM ET

    European markets were firmly in positive territory Monday, as banking stocks gained following news Northern Rock was to be nationalized. Oil-related firms also jumped as crude prices neared one-month highs.

  • Hedge Fund Gets Back To Me On Dendreon Holdings Friday, 15 Feb 2008 | 3:19 PM ET

    Even though I'm off today I, like a lot of folks, couldn't help checking my landline voicemail at work. And much to my surprise one of the messages was from Mark Gottlieb, the Chief Compliance Officer at Visium Asset Mgt. I referred to him in yesterday's post.

  • Genentech, JNJ, Pfizer: Big Days Ahead For Pharma Friday, 15 Feb 2008 | 9:41 AM ET

    Taking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.

  • Lightning Round: Dendreon, Goldman Sachs, Imax and More Thursday, 14 Feb 2008 | 7:51 PM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Dendreon Getting "The Love" From Investors Thursday, 14 Feb 2008 | 4:34 PM ET

    Early today a press release and headlines were crossing the wires about Dendreon announcing positive test results on its controversial prostate cancer drug, Provenge, at an oncology conference in San Francisco.

  • Chantix Article Author Interview Touches Nerve Thursday, 14 Feb 2008 | 11:43 AM ET

    This morning we did back-to-back interviews on "Squawk Box" with the author of the New York Magazine article about his experience on the smoking cessation drug Chantix and a Pfizer  exec to respond to it. You can watch the segment in the video clip.

  • Dendreon/Provenge Saga: There Is News After All Thursday, 14 Feb 2008 | 11:32 AM ET

    Not long after I submitted my last post I got word that the House Energy and Commerce Committee sent a letter today to the four Congressmen who had requested a hearing into the Dendreon/Provenge saga. And the answer is "no." The stock, which had been rallying on heavy volume today, sank when we broke the news on "Closing Bell."

  • There was a mini-rally and spike in volume in shares of good ol' Dendreon this morning and early afternoon. The run-up occured ahead of CEO Dr. Mitchell Gold's presentation at the BIO CEO conference in New York City at 1:15 ET.

  • One-on-One with Schering-Plough CEO Fred Hassan Wednesday, 13 Feb 2008 | 11:05 AM ET

    In a CNBC and Mad Money exclusive, Cramer sat down with Schering-Plough CEO Fred Hassan for his first interview since the controversy over the effectiveness of the cholesterol drug Vytorin. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Genentech's Avastin Study: Will It Help Get FDA Approval? Wednesday, 13 Feb 2008 | 10:29 AM ET

    After the closing bell yesterday Genentech popped out a stock-moving press release. The world's most highly-valued biotech announced that its drug Avastin when used in combo with Sanofi-Aventis' chemo drug, Taxotere, helped women with a certain type of aggressive, advanced breast cancer live longer without the disease getting worse.

  • Fujifilm Launches $1.45 Billion Bid for Toyama Chemical Wednesday, 13 Feb 2008 | 1:13 AM ET

    Digital camera and medical equipment maker Fujifilm Holdings said on Wednesday it will spend up to 155 billion yen ($1.45 billion) to take control of drug maker Toyama Chemical to grow in the pharmaceuticals market.

  • The current issue (February 18, 2008) of New York Magazine has a story that it teases on the cover above the masthead, "No Smoking Wonder Drug." Below it in drug-label fine print the sub-head is: "Makes quitter talk to potted plants."

  • Euro Stocks Rally, Financials Gain Tuesday, 12 Feb 2008 | 12:40 PM ET

    European stocks closed sharply higher Tuesday, after U.S. billionaire investor Warren Buffett inspired a late rally by offering to take on $800 billion worth of debt insured by top bond insurers.

  • Schering-Plough is bringing up the rear of big pharma earnings season this morning--it reported later than normal because it apparently took longer to do all the accounting for a big acquisition--with a beat on the top and bottom line. But investors, as is usually the case, are more concerned about guidance.

  • Schering-Plough's Loss Is Narrower than Expected Tuesday, 12 Feb 2008 | 7:55 AM ET

    Schering-Plough Tuesday reported a quarterly loss as special charges from its acquisition of Organon Biosciences late last year offset sharply higher sales, but results beat Wall Street expectations.

  • Dendreon/Provenge Petition: It Ain't Me On There Monday, 11 Feb 2008 | 12:39 PM ET

    Anyone who has followed the Dendreon/Provenge saga knows there are a lot of passionate people attached to it. And apparently one of them may go by the name Mike Huckman. Last night it was brought to my attention that my name appears (or appeared) on line 277 of this online petition.

  • Allergan "Suffering" From Adverse Botox Events Friday, 8 Feb 2008 | 4:46 PM ET

    Shares of Allergan are taking a big hit today after the Food and Drug Administration announced it's putting out an "Early Communication" (Translation: We're reviewing some reports of adverse events, but in the meantime, doctors and patients should be vigilant) regarding potentially fatal side effects of the popular muscle relaxant Botox.

  • In their stump speeches and debates, Hillary Clinton and Barack Obama often talk about pushing back against the Washington influence of the powerful pharmaceutical lobby and keeping drug company profits in check.